<table id="_RefID0EB3BG" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9: Drugs That are Affected by and Affecting Ciprofloxacin Tablets</caption>
<col width="28%"></col>
<col width="30%"></col>
<col width="40%"></col>
<tbody>
<tr>
<td align="center" colspan="3" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Drugs That are Affected by Ciprofloxacin Tablets</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Drug(s) </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Recommendation </content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Comments </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Tizanidine </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Contraindicated </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Concomitant administration of tizanidine and ciprofloxacin tablets is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine <content stylecode="italics">[see <linkhtml href="#ID_d9d5c1f3-ef04-49a7-adfe-a868e41bbd38">Contraindications (4.2)</linkhtml>]. </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Theophylline </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Avoid use </paragraph>
<paragraph>(Plasma exposure likely to be increased and prolonged) </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Concurrent administration of ciprofloxacin tablets with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#ID_0ba004d5-72e9-4be4-a6db-cb478d8fab10">Warnings and Precautions (5.9)</linkhtml>
</content>
<content stylecode="italics">]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Drugs Known to Prolong QT Interval </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Avoid use </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Ciprofloxacin tablets may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#ID_11a46bb0-5220-4fdd-bfa0-68a19c4cdd82">Warnings and Precautions (5.11)</linkhtml>
</content>
<content stylecode="italics"> and <linkhtml href="#ID_aaa8da38-adb2-4c5d-8917-2707af2dc685">Use in Specific Populations (8.5)</linkhtml>]. </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Oral Antidiabetic Drugs </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
<paragraph>Glucose-lowering effect potentiated </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Hypoglycemia sometimes severe has been reported when ciprofloxacin tablets and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were coadministered, presumably by intensifying the action of the oral antidiabetic agent. Fatalities have been reported<content stylecode="italics">. </content>Monitor blood glucose when ciprofloxacin tablets are co-administered with oral antidiabetic drugs <content stylecode="italics">[see <linkhtml href="#ID_a58674e0-255f-4457-8fe1-ada0e0cf8578">Adverse Reactions (6.1)</linkhtml>]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Phenytoin </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
<paragraph>Altered serum levels of phenytoin (increased and decreased)</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon ciprofloxacin tablets discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of ciprofloxacin tablets with phenytoin.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Cyclosporine </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
<paragraph>(Transient elevations in serum creatinine) </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Monitor renal function (in particular serum creatinine) when ciprofloxacin tablets are co-administered with cyclosporine. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Anticoagulant Drugs </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
<paragraph>(Increase in anticoagulant effect) </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin tablets to the increase in INR (international normalized ratio) is difficult to assess. Monitor prothrombin time and INR frequently during and shortly after co-administration of ciprofloxacin tablets with an oral anticoagulant (for example, warfarin). </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Methotrexate </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
<paragraph>Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>Potential increase in the risk of methotrexate associated toxic reactions. Therefore, carefully monitor patients under methotrexate therapy when concomitant ciprofloxacin tablets therapy is indicated. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Ropinirole </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin tablets <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#ID_eb08a72b-f6b1-4981-8a11-193ed65b1474">Warnings and Precautions (5.16)</linkhtml>
</content>
<content stylecode="italics">]. </content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Clozapine </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin tablets are advised. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>NSAIDs </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Sildenafil </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
<paragraph>2-fold increase in exposure </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Monitor for sildenafil toxicity <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#ID_bbdc796c-1de6-42b2-91c1-a33fb8202ff1"> Clinical Pharmacology (12.3)</linkhtml>
</content>
<content stylecode="italics">]</content>. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Duloxetine </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Avoid use </paragraph>
<paragraph>5-fold increase in duloxetine exposure </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="middle">
<paragraph>If unavoidable, monitor for duloxetine toxicity. </paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Caffeine/Xanthine Derivatives </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Use with caution </paragraph>
<paragraph>Reduced clearance resulting in elevated levels and prolongation of serum half-life </paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Ciprofloxacin tablets inhibit the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). Monitor for xanthine toxicity and adjust dose as necessary. </paragraph>
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Tablets</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx<sup>®</sup> (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Ciprofloxacin tablets should be taken at least 2 hours before or 6 hours after multivalent cation-containing products administration <content stylecode="italics">[see </content>
<content stylecode="italics">
<linkhtml href="#ID_c7dbf015-7a74-4784-b866-ed781ca357c8">Dosage and Administration (2.4)</linkhtml>
</content>
<content stylecode="italics">].</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Botrule " valign="top">
<paragraph>Decrease ciprofloxacin tablets absorption, resulting in lower serum and urine levels.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Probenecid </paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="top">
<paragraph>Use with caution</paragraph>
<paragraph>(Interferes with renal tubular secretion of ciprofloxacin tablets and increases ciprofloxacin serum levels)</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule " valign="middle">
<paragraph>Potentiation of ciprofloxacin tablets toxicity may occur.</paragraph>
</td>
</tr>
</tbody>
</table>